StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.47−0.39 (-1.35%)

Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%

Pfizer net income

Net income is the profit left for shareholders after every expense, interest and tax.

Pfizer's net income for the twelve months ending Jun 28, 2026 was $4.33B, down 59.7% year over year. For fiscal 2025 it was $7.77B, down 3.2% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $31.37B in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.77B-3.2%
FY2024Dec 31, 2024$8.03B+279.0%
FY2023Dec 31, 2023$2.12B-93.2%
FY2022Dec 31, 2022$31.37B+42.7%
FY2021Dec 31, 2021$21.98B+140.0%
FY2020Dec 31, 2020$9.16B-42.8%
FY2019Dec 31, 2019$16.03B+43.7%
FY2018Dec 31, 2018$11.15B-47.7%
FY2017Dec 31, 2017$21.31B+195.3%
FY2016Dec 31, 2016$7.22B+3.7%
FY2015Dec 31, 2015$6.96B-23.8%
FY2014Dec 31, 2014$9.14B-58.5%
FY2013Dec 31, 2013$22.00B+51.0%
FY2012Dec 31, 2012$14.57B+45.6%
FY2011Dec 31, 2011$10.01B+21.2%
FY2010Dec 31, 2010$8.26B-4.4%
FY2009Dec 31, 2009$8.64B+6.6%
FY2008Dec 31, 2008$8.10B-0.5%
FY2007Dec 31, 2007$8.14B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026-$248.00M-108.5%
Q1 FY2026Mar 29, 2026$2.69B-9.4%
Q4 FY2025Dec 31, 2025-$1.65B-502.0%
Q3 FY2025Sep 28, 2025$3.54B-20.7%
Q2 FY2025Jun 29, 2025$2.91B+6997.6%
Q1 FY2025Mar 30, 2025$2.97B-4.8%
Q4 FY2024Dec 31, 2024$410.00M–
Q3 FY2024Sep 29, 2024$4.47B–
Q2 FY2024Jun 30, 2024$41.00M-98.2%
Q1 FY2024Mar 31, 2024$3.12B-43.8%
Q4 FY2023Dec 31, 2023-$3.37B-167.5%
Q3 FY2023Oct 1, 2023-$2.38B-127.7%
Q2 FY2023Jul 2, 2023$2.33B-76.5%
Q1 FY2023Apr 2, 2023$5.54B-29.5%
Q4 FY2022Dec 31, 2022$4.99B+47.2%
Q3 FY2022Oct 2, 2022$8.61B+5.7%
Q2 FY2022Jul 3, 2022$9.91B+78.1%
Q1 FY2022Apr 3, 2022$7.86B+61.2%
Q4 FY2021Dec 31, 2021$3.39B+301.1%
Q3 FY2021Oct 3, 2021$8.15B+454.5%
Q2 FY2021Jul 4, 2021$5.56B+59.4%
Q1 FY2021Apr 4, 2021$4.88B+45.4%
Q4 FY2020Dec 31, 2020$846.00M–
Q3 FY2020Sep 27, 2020$1.47B-80.9%
Q2 FY2020Jun 28, 2020$3.49B-30.9%
Q1 FY2020Mar 29, 2020$3.36B-13.6%
Q4 FY2019Dec 31, 2019-$583.00M–
Q3 FY2019Sep 29, 2019$7.68B+86.7%
Q2 FY2019Jun 30, 2019$5.05B+30.3%
Q1 FY2019Mar 31, 2019$3.88B+9.1%
Q4 FY2018Dec 31, 2018-$393.00M-103.2%
Q3 FY2018Sep 30, 2018$4.11B+44.9%
Q2 FY2018Jul 1, 2018$3.87B+26.0%
Q1 FY2018Apr 1, 2018$3.56B+14.1%
Q4 FY2017Dec 31, 2017$12.27B+1483.7%
Q3 FY2017Oct 1, 2017$2.84B+109.6%
Q2 FY2017Jul 2, 2017$3.07B–
Q1 FY2017Apr 2, 2017$3.12B–
Q4 FY2016Dec 31, 2016$775.00M–
Q3 FY2016Oct 2, 2016$1.36B–

More Pfizer figures

See a number that looks wrong?